X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Rabeximod is is an orally administered immunomodulator being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections.
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2021
Details:
While Cyxone continues to develop the oral administration form for T20K, the company has also decided to initiate a feasibility study on a subcutaneous administration form in Q2 2021. Finally, biomarker development to support both administration forms will be completed.
Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
Professor Pitzalis will be pivotal in Cyxone’s planned clinical trial in RA indication for the compound Rabeximod. Professor Pitzalis along with a team of world-class international rheumatologists has advised Cyxone on the updated Phase 2b trial design.
Lead Product(s): Rabeximod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: William Harvey Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 04, 2021
Details:
The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery.
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market.
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Cyxone has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients.
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Rob-803
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Rob 803
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
New patent applications have been filed to extend exclusivity on Rabeximod, potentially to 2043. A patent application related to Covid-19 has also been filed.
Lead Product(s): Rabeximod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Cyxone plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients. The treatment is intended to reduce the risk of developing severe respiratory symptoms caused by virus-related overactivation of the immune system.
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
The agreement will support Cyxone to develop their drug candidates T20K and Rabeximod and bring them closer to the market.
Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Professor Rikard Holmdahl
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
